Congratulations to Dr. James Lechleiter, professor in the Department of Cell Systems and Anatomy and the inventor and patent holder on technology licensed to Astrocyte Pharmaceuticals.

Astrocyte Pharmaceuticals was mentioned on MedCityNews for completing a Series A funding that raised six million to advance next generation stroke and traumatic brain injury treatment to the clinic.

The company’s lead therapeutic is based on technology originally licensed from University of Texas Health Science Center at San Antonio, to address the unmet need for a drug that can reduce injury to the brain resulting from stroke, traumatic brain injury, concussion and other neurodegenerative conditions. Funding will be used to bring the therapeutic to Phase 1 human trials.

To see the article, click here.